FDA slaps a hold on Sarepta’s Duchenne MD study in the wake of stellar early results

Just days after Sarepta $SRPT managed to whip up intense excitement over early-stage data from its first human study of their gene therapy for Duchenne muscular dystrophy, the biotech reported that the FDA has put the program on hold.